J
Jolien Tol
Researcher at Bosch
Publications - 62
Citations - 4883
Jolien Tol is an academic researcher from Bosch. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 24, co-authored 47 publications receiving 4453 citations. Previous affiliations of Jolien Tol include Radboud University Nijmegen Medical Centre & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol,Miriam Koopman,Annemieke Cats,C.J. Rodenburg,Geert Jan Creemers,Jolanda G Schrama,Frans L. G. Erdkamp,A. Vos,Cees J van Groeningen,Harm Sinnige,Dirk J. Richel,Emile E. Voest,Jeroen R. Dijkstra,Marianne E. Vink-Börger,Ninja Antonini,Linda Mol,Johan H. J. M. van Krieken,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life.
Journal ArticleDOI
BRAF mutation in metastatic colorectal cancer.
TL;DR: In a subgroup of 520 patients with available tumor samples, it was found that progression-free survival was shorter among patients with metastatic colorectal cancer treated with chemotherapy, bevacizumab, and cetuximab (CBC regimen) than among patients who received chemotherapy and bevacsumab alone (CB regimen).
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
Nikki Knijn,Leonie J. M. Mekenkamp,M Klomp,M E Vink-Börger,Jolien Tol,Steven Teerenstra,Jos W. R. Meijer,M Tebar,S Riemersma,J.H.J.M. van Krieken,C.J.A. Punt,Iris D. Nagtegaal +11 more
TL;DR: Both primary tumours and liver metastases can be used for KRAS mutation analysis, and the concordance of test results between primary tumour and corresponding metastases is high.
Journal ArticleDOI
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
Geraldine Gebhart,Laetitia E. Lamberts,Zena Wimana,Camilo Garcia,Patrick Emonts,Lieveke Ameye,Sigrid Stroobants,Manon T. Huizing,Philippe Aftimos,Jolien Tol,Wim J.G. Oyen,Danielle J. Vugts,Otto S. Hoekstra,Carolien P. Schröder,C. W. Menke-van der Houven van Oordt,Thomas Guiot,Adrienne H. Brouwers,Ahmad Awada,E.G.E. de Vries,Patrick Flamen +19 more
TL;DR: Pretreatment imaging of HER2 targeting, combined with early metabolic response assessment holds great promise for improving the understanding of tumor heterogeneity in mBC and for selecting patients who will/will not benefit from T-DM1.